Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan
Crossref DOI link: https://doi.org/10.1007/s40272-017-0264-y
Published Online: 2017-09-11
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kashiwagi, Tomoko
Okada, Yukiko
Nomoto, Ken
Funding for this research was provided by:
AbbVie GK, Tokyo, Japan
License valid from 2017-09-11